Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Net Cash Flow (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Net Cash Flow for 6 consecutive years, with $101.0 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 81.64% to $101.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $82.7 million through Dec 2025, up 74.81% year-over-year, with the annual reading at $82.7 million for FY2025, 74.81% up from the prior year.
  • Net Cash Flow for Q4 2025 was $101.0 million at Inhibikase Therapeutics, up from -$39.5 million in the prior quarter.
  • The five-year high for Net Cash Flow was $101.0 million in Q4 2025, with the low at -$39.5 million in Q3 2025.
  • Average Net Cash Flow over 5 years is $6.3 million, with a median of -$2.1 million recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 694632.18% in 2021, while the deepest fall reached 81674.89% in 2021.
  • Over 5 years, Net Cash Flow stood at -$4.1 million in 2021, then soared by 134.34% to $1.4 million in 2022, then tumbled by 504.95% to -$5.7 million in 2023, then skyrocketed by 1075.7% to $55.6 million in 2024, then surged by 81.64% to $101.0 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $101.0 million, -$39.5 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.